IL223150D0 - Method for preparing an enriched igg composition from plasma - Google Patents

Method for preparing an enriched igg composition from plasma

Info

Publication number
IL223150D0
IL223150D0 IL223150A IL22315012A IL223150D0 IL 223150 D0 IL223150 D0 IL 223150D0 IL 223150 A IL223150 A IL 223150A IL 22315012 A IL22315012 A IL 22315012A IL 223150 D0 IL223150 D0 IL 223150D0
Authority
IL
Israel
Prior art keywords
plasma
preparing
method
igg composition
enriched igg
Prior art date
Application number
IL223150A
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to AU2010202125A priority Critical patent/AU2010202125B1/en
Priority to PCT/US2010/036470 priority patent/WO2011149472A1/en
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of IL223150D0 publication Critical patent/IL223150D0/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42727304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL223150(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/36Extraction; Separation; Purification by a combination of two or more processes of different types
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/16Blood plasma; Blood serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/30Extraction; Separation; Purification by precipitation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/18Ion-exchange chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/34Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
IL223150A 2010-05-26 2012-11-20 Method for preparing an enriched igg composition from plasma IL223150D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2010202125A AU2010202125B1 (en) 2010-05-26 2010-05-26 A method to produce an immunoglobulin preparation with improved yield
PCT/US2010/036470 WO2011149472A1 (en) 2010-05-26 2010-05-27 Method for preparing an enriched igg composition from plasma

Publications (1)

Publication Number Publication Date
IL223150D0 true IL223150D0 (en) 2013-02-03

Family

ID=42727304

Family Applications (2)

Application Number Title Priority Date Filing Date
IL223149A IL223149D0 (en) 2009-07-23 2012-11-20 Removal of serine proteases by treatment with finely divided silicon dioxide
IL223150A IL223150D0 (en) 2010-05-26 2012-11-20 Method for preparing an enriched igg composition from plasma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL223149A IL223149D0 (en) 2009-07-23 2012-11-20 Removal of serine proteases by treatment with finely divided silicon dioxide

Country Status (23)

Country Link
US (4) US8993734B2 (en)
EP (5) EP2445482B1 (en)
JP (6) JP5876474B2 (en)
KR (3) KR101647617B1 (en)
CN (5) CN102970975B (en)
AR (2) AR076800A1 (en)
AU (5) AU2010202125B1 (en)
BR (2) BR112012029893A2 (en)
CA (2) CA2800155A1 (en)
CL (3) CL2012003290A1 (en)
CO (2) CO6660439A2 (en)
DK (3) DK2445482T3 (en)
EA (4) EA201500848A1 (en)
ES (3) ES2525492T3 (en)
HK (6) HK1170168A1 (en)
HR (3) HRP20140944T1 (en)
IL (2) IL223149D0 (en)
MX (3) MX349815B (en)
MY (2) MY160551A (en)
PT (3) PT2554160E (en)
SG (3) SG185724A1 (en)
TW (3) TWI531577B (en)
WO (1) WO2011149472A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI489994B (en) 2008-03-17 2015-07-01 Baxter Healthcare Sa Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
PL2477603T3 (en) * 2009-09-17 2016-10-31 Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Baxalta GmbH A method to produce an immunoglobulin preparation with improved yield
JP5830096B2 (en) * 2010-07-23 2015-12-09 バクスター、インターナショナル、インコーポレイテッド Method for producing plasma-derived inter-alpha inhibitor protein (IaIp)
AU2011364724B2 (en) * 2011-04-08 2016-11-17 Universidad De Costa Rica Method for producing injectable formulations of blood-derived protein materials, and materials obtained using said method
TW201339578A (en) 2011-12-13 2013-10-01 Baxter Int Measurement of autoantibodies at low conductivity with increased sensitivity
TWI629283B (en) 2012-02-23 2018-07-11 巴克斯歐塔公司 Fraction i-iv-1 precipitation of immunoglobins from plasma
RU2487725C1 (en) * 2012-03-15 2013-07-20 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации (ФГУП "НПО "Микроген" Минздрава России) Method for preparing concentrated immunoglobulin preparation for subcutaneous application
CN103197053B (en) * 2013-03-15 2015-02-18 上海市血液中心 Anti-IgA antibody detection kit
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Baxalta GmbH Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
CN104086646B (en) * 2014-07-03 2018-10-09 成都蓉生药业有限责任公司 The preparation method that FV is precipitated in blood product
CN104072601A (en) * 2014-07-03 2014-10-01 成都蓉生药业有限责任公司 Preparation method of FII sediment in blood product
CN104086642A (en) * 2014-07-03 2014-10-08 成都蓉生药业有限责任公司 Method for preparing FI+III supernatants in blood products
CN204424090U (en) 2014-11-28 2015-06-24 比亚迪股份有限公司 Film Capacitors
WO2016161421A1 (en) * 2015-04-02 2016-10-06 Kieu Hoang A method of manufacturing intravenous immunoglobulin from fraction iii
CN107847541A (en) * 2015-04-02 2018-03-27 K·黄 Clone and be further purified in the method for Prepare restructuring intravenous injection of immunoglobulin
CN107921080A (en) * 2015-04-02 2018-04-17 K·黄 Manufactured by component III and be purified into the method for the prothrombin complex concentrating agents for intravenous injection and treat and prevent the haemophilia A with inhibitor or infected the method for the haemophilia B patient of HIV 1 and HIV 2
WO2017062536A2 (en) * 2015-10-06 2017-04-13 Kieu Hoang A method of manfacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390074A (en) * 1942-02-09 1945-12-04 Research Corp Protein product and process
SE348942B (en) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US4056614A (en) 1972-09-22 1977-11-01 Marc Bonneau Immunity depressant medicine
US3998946A (en) * 1975-04-23 1976-12-21 The Regents Of The University Of Minnesota Fibrinogen-free plasminogen-plasmin-free plasma and method of preparing and using same
DE2801123C2 (en) * 1977-01-26 1986-01-02 Armour Pharma Gmbh & Co Kg, 3440 Eschwege, De
US4296027A (en) * 1977-08-31 1981-10-20 The Regents Of The University Of Minnesota Pure intravenous human and animal gamma globulins
US4136094A (en) 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
US4550019A (en) * 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
DE2901822A1 (en) * 1979-01-18 1980-07-31 Biotest Serum Institut Gmbh A method for producing a for intravenous administration suitable immunoglobulin solution that contains IgM in form ankonzentrierter
US4378346A (en) * 1979-08-15 1983-03-29 Tankersley Donald L Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production
US4499073A (en) * 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
DK166763C (en) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-G-containing fraction
DE3523615C2 (en) 1985-07-02 1988-02-04 Cytomed Medizintechnik Gmbh, 8750 Aschaffenburg, De
US5061237A (en) 1985-07-02 1991-10-29 Cytomed Medizintechnik Gmbh Method of purifying whole blood
JPH0742235B2 (en) 1985-11-08 1995-05-10 三共株式会社 Agent for the prophylaxis or treatment of autoimmune diseases
US5136094A (en) 1988-03-10 1992-08-04 Air Products And Chemicals, Inc. Process for the synthesis of secondary formamides
JP2871709B2 (en) 1988-11-21 1999-03-17 住友製薬株式会社 Novel protein protein h, preparation of genes and protein encoding the protein having an immunoglobulin g avidity
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
EP0440509A3 (en) * 1990-02-02 1991-12-18 Common Services Agency Novel cell growth medium components and process for producing same
US5130451A (en) * 1991-03-28 1992-07-14 Amoco Corporation Process for preparing carboxyaryl phosphates
US5324425A (en) * 1992-08-26 1994-06-28 Ellison Billy L Method and apparatus for removing solids from aqueous wash solutions
FR2706466B1 (en) 1993-06-14 1995-08-25 Aetsrn Immunoglobulin G concentrate for therapeutic use and process for producing said concentrate.
US5610285A (en) 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
AUPN858596A0 (en) * 1996-03-08 1996-04-04 Csl Limited Filtration of plasma precipitates using cellulose filter aid
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5783640A (en) * 1997-03-04 1998-07-21 The Goodyear Tire & Rubber Company Rubber compositions containing a disodium salt of 2, 2'-dithiosalicyclic acid
TW541179B (en) 1997-03-19 2003-07-11 Green Cross Corp Process for preparing immunoglobulin preparation
AT407114B (en) 1997-06-10 2000-12-27 Immuno Ag Alpha 1-antitrypsin-preparation-as well as process for their preparation
US5886154A (en) * 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
DK0911037T3 (en) 1997-10-23 2002-12-02 Mitsubishi Pharma Corp At room temperature storage durable immunoglobulin preparation for intravenous injection
US20020114802A1 (en) 1998-02-10 2002-08-22 Tjellstrom Bo Arthur Einar Oral immunoglobulin treatment for inflammatory bowel disease
AT406873B (en) 1998-02-25 2000-10-25 Immuno Ag A method for the depletion of pathogenic from protein-containing solutions
US6413245B1 (en) 1999-10-21 2002-07-02 Alcon Universal Ltd. Sub-tenon drug delivery
DE10008519C1 (en) 2000-02-21 2001-07-12 Dica Technologies Ag Secure E-mail communication method for internet uses security association listing with security parameters fed back to communication device of transmission domain when no listing exists for target domain
DE10008619A1 (en) * 2000-02-24 2001-09-06 Immuno Vet As Lynge Microorganism-free Immunoglobulin (Ig) G preparation produced from animal blood, used for prevention of bacterial and viral infections in animal husbandry
SE0001128D0 (en) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
US20020098182A1 (en) 2000-09-28 2002-07-25 Richard Weisbart Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G
FR2824568B1 (en) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement human immunoglobulin concentrates Preparation Method has therapeutic use
US20030099635A1 (en) 2001-10-04 2003-05-29 Protein Therapeutics, Inc. Use of oral gammaglobulin for the treatment of immune-mediated diseases
US7777006B2 (en) * 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
US20050054003A1 (en) 2003-09-10 2005-03-10 Stenland Christopher J. Prion clearance using particulate metal oxides
JP2008500959A (en) 2004-01-30 2008-01-17 スオメン プナイネン リスティ ヴェリパルヴェル Immunoglobulin production method safe for viruses
BRPI0508096B1 (en) 2004-02-27 2019-04-02 Octapharma Ag Method of preparing a purified virus and inactivated safe antibody preparation
US8088579B2 (en) 2005-02-14 2012-01-03 University Of Iowa Research Foundation Complement factor H for diagnosis of age-related macular degeneration
US8715649B2 (en) 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
US7807435B2 (en) 2005-08-11 2010-10-05 Baxter International Inc. Method for the purification of alpha-1 proteinase inhibitor (a1PI)
EP1928483B1 (en) 2005-09-19 2016-12-28 CSL Behring GmbH Factor h for the treatment of tubulointerstitial fibrosis and progressive renal failure
FR2894145B1 (en) 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Use of factor h of the complement as a medicinal product
AU2007209363B2 (en) * 2006-01-25 2013-08-22 Octapharma Ag Purification and use of a factor for supporting wound healing
DE102007001521A1 (en) * 2007-01-10 2008-07-17 Matthias, Torsten, Dr. Use of Cohn-Oncley fractions II and II / III for the treatment of systemic lupus erythematosus
WO2008113589A1 (en) 2007-03-20 2008-09-25 Csl Behring Gmbh Methods for industrial scale production of therapeutic complement factor h preparations from human plasma
DE202007004346U1 (en) 2007-03-21 2007-10-31 Rehau Ag + Co pipe arrangement
CA2722015A1 (en) * 2007-04-20 2009-01-08 Regents Of The University Of Colorado Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
EP2522753B1 (en) 2007-08-13 2014-04-02 Baxter International Inc. IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease
AU2008307144B2 (en) * 2007-10-02 2012-12-20 Csl Limited Therapeutic antibody purification method and method of use
CN101249265B (en) * 2008-04-11 2010-10-27 三九集团湛江开发区双林药业有限公司 Intravenous injection employ persons hepatitis B immune globulin and method of preparing the same
CN201169579Y (en) * 2008-06-30 2008-12-24 山东泰邦生物制品有限公司 Ethanol atomizing diffusion apparatus for separating human serum albumin
US9783792B2 (en) * 2008-11-12 2017-10-10 Baxalta Incorporated Purification of butyrylcholinesterase using membrane adsorption
EP2762492A3 (en) 2009-05-27 2015-03-18 Baxter International Inc A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
US8304524B2 (en) 2009-07-23 2012-11-06 Baxter International Inc. Manufacture of factor H (FH) and FH-derivatives from plasma
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Baxalta GmbH A method to produce an immunoglobulin preparation with improved yield
JP5830096B2 (en) * 2010-07-23 2015-12-09 バクスター、インターナショナル、インコーポレイテッド Method for producing plasma-derived inter-alpha inhibitor protein (IaIp)

Also Published As

Publication number Publication date
AU2011258111A1 (en) 2012-12-13
EA025826B1 (en) 2017-02-28
HK1181682A1 (en) 2015-10-02
US20110293638A1 (en) 2011-12-01
PT2445482E (en) 2014-11-03
DK2554160T3 (en) 2015-04-27
JP2016155798A (en) 2016-09-01
MX2012013689A (en) 2013-01-28
MY160551A (en) 2017-03-15
EP2554160A1 (en) 2013-02-06
US8993734B2 (en) 2015-03-31
JP2016053016A (en) 2016-04-14
EA201291367A1 (en) 2013-09-30
EA201291355A1 (en) 2013-04-30
AU2016202973A1 (en) 2016-05-26
JP2018080207A (en) 2018-05-24
AU2010202125B1 (en) 2010-09-02
BR112012029893A2 (en) 2019-05-28
AU2016202973B2 (en) 2017-12-07
EP2445482B1 (en) 2014-08-27
KR20160014119A (en) 2016-02-05
JP6363676B2 (en) 2018-07-25
EP2575762A2 (en) 2013-04-10
JP2013527201A (en) 2013-06-27
WO2011149472A1 (en) 2011-12-01
CN103068365A (en) 2013-04-24
CL2014003430A1 (en) 2015-05-04
ES2525492T3 (en) 2014-12-23
US8940877B2 (en) 2015-01-27
DK2575762T3 (en) 2014-10-13
CL2012003290A1 (en) 2013-10-18
HRP20150484T1 (en) 2015-08-14
EP2445482A1 (en) 2012-05-02
CA2800272A1 (en) 2011-12-01
JP5866345B2 (en) 2016-02-17
IL223149D0 (en) 2013-02-03
EP2803349A1 (en) 2014-11-19
ES2505465T3 (en) 2014-10-10
CO6660439A2 (en) 2013-04-30
MX349815B (en) 2017-08-09
CN109180776A (en) 2019-01-11
SG185724A1 (en) 2013-01-30
DK2445482T3 (en) 2014-09-22
CA2800155A1 (en) 2011-12-01
TWI543989B (en) 2016-08-01
EA201691558A1 (en) 2017-05-31
HRP20140944T1 (en) 2014-12-05
CL2012003291A1 (en) 2013-10-04
EA201500848A1 (en) 2016-06-30
AU2011258111B2 (en) 2016-02-11
TW201141879A (en) 2011-12-01
TW201202263A (en) 2012-01-16
AU2010224461B2 (en) 2011-08-04
EP2575762B1 (en) 2014-07-09
HK1170168A1 (en) 2015-01-30
TW201542584A (en) 2015-11-16
AU2010224461A1 (en) 2010-10-21
KR101593265B1 (en) 2016-02-11
HK1183449A1 (en) 2015-01-30
MY161617A (en) 2017-04-28
BR112012029897A2 (en) 2016-08-16
KR101647617B1 (en) 2016-08-10
EA023446B1 (en) 2016-06-30
KR101716534B1 (en) 2017-03-14
MX337028B (en) 2016-02-09
HK1215931A1 (en) 2016-09-30
HRP20141109T1 (en) 2014-12-19
CN104958761A (en) 2015-10-07
PT2575762E (en) 2014-07-28
ES2536093T3 (en) 2015-05-20
HK1203838A1 (en) 2015-11-06
AU2018201371B2 (en) 2019-10-31
CN102970975B (en) 2015-05-06
CN103068365B (en) 2015-07-08
US20150133644A1 (en) 2015-05-14
TWI504607B (en) 2015-10-21
JP2013528183A (en) 2013-07-08
AR076800A1 (en) 2011-07-06
KR20130109016A (en) 2013-10-07
KR20130080450A (en) 2013-07-12
PT2554160E (en) 2015-06-11
JP2017014297A (en) 2017-01-19
SG185725A1 (en) 2012-12-28
SG10201505161SA (en) 2015-08-28
CO6660438A2 (en) 2013-04-30
AR082093A1 (en) 2012-11-14
US20180118782A1 (en) 2018-05-03
MX364252B (en) 2019-04-17
EP2554160B1 (en) 2015-02-25
HK1213790A1 (en) 2016-07-15
EP2796128A1 (en) 2014-10-29
JP6592120B2 (en) 2019-10-16
CN102970975A (en) 2013-03-13
AU2018201371A1 (en) 2018-03-22
CN104840946A (en) 2015-08-19
TWI531577B (en) 2016-05-01
US20130101579A1 (en) 2013-04-25
MX2012013682A (en) 2013-01-28
JP5876474B2 (en) 2016-03-02

Similar Documents

Publication Publication Date Title
EG27059A (en) Method for separating independent simultaneous sources
EP2635880A4 (en) Method and apparatus for spectrometry
IL223822A (en) Process for separation of gases
EP2558923A4 (en) Extension framework for input method editor
HK1180152A1 (en) Method for synchronized content playback
EP2572811A4 (en) Method for press-forming l-shaped components
EP2608541A4 (en) Method for decoding intra-predictions
ZA201401133B (en) Method for producing ternesite
PL391416A1 (en) Method for graphene preparation
EP2563907A4 (en) Methods for generating cardiomyocytes
ZA201305971B (en) Method for the purification of biphephos
DK2445482T3 (en) Process for Preparation of Enriched Plasma IgG Composition
EP2740064A4 (en) Sandboxing technology for webruntime system
SG10201601048UA (en) Methods, apparatus, and system for mass spectrometry
GB2500163B (en) Method
EP2552873A4 (en) Method for making hexafluoro-2-butene
EP2721187A4 (en) Method for the manufacture of alpha-beta ti-al-v-mo-fe alloy sheets
AP201407417A0 (en) Sealing mechanism and method for drop cable spliceenclosures
PT2612859E (en) Method for producing 1-triazole-2-butanol derivative
HU1000330D0 (en) Novel method
EP2668136A4 (en) Method for the preparation of high purity stannous oxide
GB201012605D0 (en) Method & system
IL227593A (en) Method for preparing noribogaine from voacangine and purification thereof
PL2563751T3 (en) Method for producing tetrafluoropropenes
SG11201403605PA (en) Method for separating gases